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Purpose: Hangeshashinto (TJ-14), a Kampo medicine comprising seven types of herbs, has
been used in Japan to alleviate the side effects associated with anticancer drug treatments.
However, the pharmacological effects of this medicine currently remain unclear. The present
study aimed to demonstrate the efficacy of TJ-14 against anticancer drug-induced stomatitis,
the pain associated with which may have a negative impact on mastication and swallowing.
Methods: Mucositis was induced in Sprague-Dawley rats by cancer chemotherapy. Changes
in body weight, stomatitis grades, histopathological scores, and oral bacterial counts were
examined among TJ-14-treated, saline-treated, and Control (no treatment) rats. In vitro
studies, including cell proliferation and wound healing assays, using epidermal keratinocyte
and fibroblast cell lines were conducted.
Results: The local application of TJ-14 exerted strong antibacterial effects and attenuated
oral chemotherapy-induced stomatitis in rats. TJ-14 also increased the viability and invasion
of epidermal keratinocytes and fibroblasts.
Conclusion: The present results demonstrated the potential of TJ-14 to attenuate chemother-
apy-induced stomatitis.
Keywords: cancer chemotherapy, mucositis, Hangeshashinto, TJ-14, Kampo medicine,
traditional Japanese medicine, oral cancer
Introduction
Significant advances have been achieved in the development of new anticancer
agents and combination radiotherapy protocols to treat cancer;1,2 however, treat-
ments for the side effects associated with these therapies remain limited.3 Previous
studies reported that the incidence rates of oral mucositis, a common side effect of
anticancer therapy, were 25–55%, 70–90%, and almost 100% in patients treated
with anticancer agents for solid cancer, high-dose anticancer agents for hemato-
poietic stem cell transplantation, and anticancer agents and radiotherapy for head
and neck cancer, respectively.1,4,5 Pain associated with stomatitis has a negative
impact on mastication and swallowing, and, thus, nutrition, which reduces the
quality of life of patients and increases their susceptibility to infections.6 Previous
studies reported that stomatitis is a dose-limiting factor of cancer treatment,7
increases infection-related mortality,8 and may necessitate the withdrawal of or
changes to treatment.9
Chemotherapy-induced stomatitis has been attributed to both primary and sec-
ondary causes, with the former being caused by mucosal inflammation as a result of
reactive oxygen species generated by anticancer agents destroying cells in the oral
mucosa, and the latter to large numbers of oral bacteria adhering to the ulcerated
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surface of the mucosa and causing local infections. These
local infections, when combined with the metabolic
damage and increased susceptibility to infections caused
by anticancer agents, may become intractable or serious.10
Although various animal models have been employed to
investigate stomatitis,11 the etiology of chemotherapy-
induced stomatitis has not yet been elucidated in detail
and may be more complex than originally considered.12
Few evidence-based studies have been conducted on
the relationship between stomatitis and cancer treatments,
and effective, reliable methods for the treatment of this
condition have not been established. In clinical practice,
there is no standard treatment for chemotherapy-induced
oral mucositis, so currently symptomatic treatments are
actually employed. The prophylactic measures and treat-
ments for this disease reported so far include oral care,
nutritional therapy, topical steroid ointment, cryotherapy,
low-level laser therapy and azulene sulfonate sodium
hydrate, as well as the mouth rinse with allopurinol, camo-
stat mesylate, and rebamipide for removing active oxygen
species and protecting mucous membranes. However, their
effects are limited, which often makes the treatment
difficult.13 Mouth rinse with lidocaine hydrochloride, as
well as acetaminophen, NSAIDs, and opioids are also used
for pain management, but they are not definitive cares. In
recent years, the effectiveness of palifermin, a keratinocyte
growth factor-1, for this disease has been reported and
raising expectation. However, it has not been approved in
Japan. In addition, its use means the administration of
growth factors to the patients with malignant tumors, of
which the safety has not been established yet.13 Kampo
medicine (traditional Japanese medicine) has been used to
treat the side effects associated with anticancer drug treat-
ments in Japan.14,15 Hangeshashinto (TJ-14) has been
empirically reported to attenuate the side effects associated
with cancer chemotherapies.13,15,16 It comprises seven her-
bal extracts (Coptis rhizome, ginseng, glycyrrhiza, jujube,
Pinellia tuber, processed ginger, and Scutellaria root) and
has been approved for the treatment of acute and chronic
gastrointestinal catarrh, fermentative diarrhea, and acute
gastroenteritis and oral mucositis by the Ministry of
Health, Labour and Welfare of Japan.17 TJ-14 reportedly
promotes the healing of stomatitis induced by lung,18
colon,19 stomach,20 and head and neck cancer15 treat-
ments, and suppresses its exacerbation. A double-blind,
randomized, Phase II clinical trial for the chemotherapies
for colorectal19 and gastric20 cancers has reported that
TJ-14 reduced the severity of these diseases and shortened
the periods for healing compared with placebo controls.
However, the mechanism for the improvement of stomati-
tis by TJ-14 and its pharmacological effects still remain
unclear. Recent studies reported the antioxidant,21 anti–
inflammatory,22 bactericidal,23 analgesic17 and healing-
promoting24 effects of TJ-14.
In the present study, we used an animal model of
mucositis induced by cancer chemotherapy to investigate
the effects of TJ-14 on stomatitis. In vitro studies were




TJ-14 (serial number: J08372) was obtained from Tumura
& Co. (Tokyo, Japan) and diluted to 100 mg/mL in dis-
tilled water.
Animals
All procedures using live animals conformed to the ethical
guidelines established by the Japanese Council on Animal
Care and were approved by the Animal Care Committee of
Tokyo Dental College (permit number 282403). Fourteen-
week-old male Sprague-Dawley rats (n = 21) were obtained
from Sankyo Laboratory (Tokyo, Japan). Animals were
housed in a room maintained under standardized light
(12:12-h light/dark cycle), temperature (23 ± 2°C), and
humidity (55% ± 5%) conditions and food pellets and
drinking water were available ad libitum.1
Animal Model for Mucositis Induced by
Cancer Chemotherapy
The protocol used to induce oral mucositis was modified
from a previously reported method.1,25 5-FU (Wako Pure
Chemical Industries, Osaka, Japan) was administered intra-
peritoneally to all rats at 60 mg/kg/day on Days 1–5.
Anesthesia was induced on Day 6 by the inhalation of 4%
sevoflurane (Maruishi Pharmaceutical, Osaka, Japan), fol-
lowed by an intraperitoneal injection of sodium pentobarbi-
tal (30 mg/kg body weight, Somnopentyl; Kyoritsu Seiyaku,
Tokyo, Japan). Fifty microliters of 100% acetic acid (Wako
Pure Chemical Industries) was then applied to the lingual
dorsum with a Plaut brush® (Oral Care, Tokyo, Japan) and
rubbed in to induce stomatitis. Animals were then divided
into three groups (n = 7 each): control (no treatment); saline-
treated; and TJ-14-treated. After the development of stoma-
titis, mouths were rinsed four times daily (every 6 h) with
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physiological saline in the saline group and with TJ-14 in the
TJ-14 group using a Doltz EW1211® water flosser
(Panasonic Healthcare, Tokyo, Japan) at a water pressure
of 4.0 kgf/cm2. Body weights were measured on Days 6, 9,
11, and 16. Stomatitis grades and bacterial counts were
assessed before rinsing 3, 5, and 10 days after acetic acid
irritation (Days 9, 11, and 16, respectively).
Stomatitis Grading
A modified version of the National Cancer Institute-
Common Terminology Criteria for Adverse Events26 was
used to grade chemotherapy-induced oral mucositis in rats
on Days 9, 11, and 16 (before mouth rinsing) as follows:1
Grade 0, normal mucosa; Grade 1, redness of the mucosa
with punctate ulcers or a pseudomembrane; Grade 2, con-
fluent ulceration or a pseudomembrane with no bleeding
following a slight stimulation; Grade 3, confluent ulcera-
tion or a pseudomembrane with bleeding following a slight
stimulation; and Grade 4, tissue necrosis or spontaneous
bleeding (Figure 1A).
Histopathological Analysis of Oral
Mucositis
Tongue samples were collected from rats for
a histopathological analysis 3, 5, and 10 days after acetic
acid irritation (Days 9, 11, and 16, respectively). Specimens
were fixed in 10% neutral-buffered formalin, dehydrated,
and embedded in paraffin. Five-micrometer-thick sections
were obtained for hematoxylin and eosin staining and exam-
ined under a light microscope (×40). Histological parameters
were assessed in a single-blind manner and graded as
follows:27 Score 0, a normal epithelium and connective
tissue with no vasodilatation, cellular infiltration, hemorrha-
gic areas, ulceration, or abscesses; Score 1, mild vasodilata-
tion, re-epithelization areas and inflammatory infiltration
with large numbers of mononuclear cells, and no hemorrha-
gic areas, edema, ulceration, or abscesses; Score 2, moderate
vasodilatation, areas of hydropic epithelial degeneration,
inflammatory infiltration with large numbers of neutrophils,
the presence of hemorrhagic areas, edema, and eventual
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Score 0 Score 1 Score 2 Score 3
A
B
Figure 1 Rat chemotherapy-induced stomatitis grading and scoring criteria.
Notes: (A) Representative examples from Grades 0 to 4 are shown; (B) Representative examples from Scores 0 to 3 are shown.
Dovepress Ozawa et al
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ulceration, and no abscesses; and Score 3, severe vasodilata-
tion, inflammatory infiltration with large numbers of neutro-
phils, the presence of hemorrhagic areas, edema, and
extensive ulceration, and abscesses (Figure 1B).
Oral Bacterial Counts
Oral bacterial counts were assessed before rinsing 3, 5, and
10 days after acetic acid irritation (Days 9, 11, and 16,
respectively). Bacterial counts were measured in the oral
cavity using a bacteria detection apparatus (DU-AA01;
Panasonic Healthcare), as described previously.28 Bacterial
counts was assessed using the dielectrophoretic impedance
measurement technique.1,29
Statistical Analysis
The distribution of weight (g) on Day 6 and bacterial
counts (×105 cfu/mL) on Day 9 were tested for normality
using the Shapiro–Wilk test. Weight and stomatitis grading
were determined and the significance of differences among
the three groups was examined using the Kruskal–Wallis
test. Comparisons between two groups were performed
using the Mann–Whitney U-test followed by the Steel-
Dwass test. Oral bacteria were counted, and differences
among all three groups were investigated using an analysis
of variance. Comparisons between two groups were made
using the t-test, and p values were adjusted using Tukey’s
method. SAS version 9.4 statistical software (SAS
Institute, Cary, NC) was used for statistical analyses,
with p < 0.05 (two-tailed) considered to be significant.1
Anti-Inflammatory Effects of TJ-14 in the
Experimental Inflammatory Rat Model
Phorbol 12-myristate 13-acetate (PMA; 5 mg; Sigma,
St. Louis, MO) was dissolved in 250 μL of dimethyl
sulfoxide (DMSO) in accordance with a previous study.30
A total of 1.59 mL of acetone was added to 10 μL of this
solution to obtain a PMA solution (125 μg/mL), 10 μL of
which was applied to the right and left auricles of healthy
rats. TJ-14 was then applied to both sides of the right
auricle once every hour, and the swelling inhibition rate
was calculated after 6 h. Ice water was applied to both
sides of the right auricle in the controls. The swelling
inhibition rate was calculated using the following formula:
suppression rate of swelling (%) = [left auricle thickness
(mm) - right auricle thickness (mm)]/left auricle thickness
(mm) ×100 (%).
Cells
The PSVK1 epidermal keratinocyte cell line and KD
fibroblast cell line, obtained from the Japanese Collection
of Research Bioresources Cell Bank, Osaka, Japan, were
maintained in 150 × 20-mm tissue culture dishes (Nunc,
Roskilde, Denmark) at 37°C (humidified atmosphere, 5%
CO2/95% air) and cultured in Dulbecco’s modified Eagle’s
medium (Sigma) with 10% fetal bovine serum (Sigma)
and 50 units/mL penicillin and streptomycin.
Cell Proliferation Assay
PSVK1 and KD cells were plated onto 96-well plates (den-
sity, 5 ×103 cells/well) in sextuplicate and incubated at 37°C
in a humidified 5% CO2 atmosphere. After an overnight
attachment period, the cells were treated with TJ-14 (30,
100, or 300 μg/mL) or 0.01% DMSO (as a control). The
number of viable cells was counted at 24, 48, and 72 h using
the RealTime-Glo MT Cell Viability Assay (Promega
Corporation, Wisconsin, USA) and a GloMax 96
Microplate Luminometer (Promega Corporation). All assays
were performed in five technical replicates and each assay
was repeated three times.
Wound Healing Assay
PSVK1 and KD cells were seeded at 3.0 ×105 cells/insert on
culture inserts (80206; ibidi GmbH, Munich, Germany) in
triplicate and then exposed to TJ-14 (30, 100, 300 μg/mL) or
0.01% DMSO. Wound healing was assessed as described in
our previous study.31 The closure of the gap that was created
during the cell culture was viewed under a microscope
(200× magnification) and immediately photographed after
the same culture medium had been added at the indicated
time points. The area of the gap was measured at each time
point using the MTrackJ plugin (http://www.imagescience.
org/meijering/software/mtrackj/manual/) in ImageJ software
(version 1.50; NIH, Bethesda, MA).
Results
Data Distribution
The Shapiro–Wilk test was significant (p=0.0004) for body
weight on Day 6, but not for bacterial counts on Day 9
(p=0.0068).
Body Weight Changes
Body weight decreased after the development of stomatitis
in all rats in the three groups (Figure 2A). Significant
differences were observed in body weight on Day 16
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between the Control and TJ-14 groups and the saline and
TJ-14 groups (p < 0.05). Within-group comparisons
revealed significant differences in body weight between
Day 6 and Days 9 and 11 in the three groups (p < 0.05).
Significant differences were also noted between Days 6
and 16 in the Control and saline groups.
Stomatitis Grading
Stomatitis grades were the lowest on Days 11 and 16 in the
TJ-14 group (Figure 2B). Grades did not improve during
the experimental period in the Control group. In the saline
group, no significant change in grade was observed on Day
11, whereas improvements were noted on Day 16. In the
TJ-14 group, stomatitis grades improved on Days 11 and
16, exhibiting overall improvements with time. Significant
differences were observed on Days 11 and 16 between the
Control and TJ-14 groups and the saline and TJ-14 groups
(Figure 2B). Intragroup comparisons revealed significant
differences between Days 9 and 16 in the TJ-14 group.
Histopathological Scoring
Histopathological scores were the lowest on Days 11 and 16
in the TJ-14 group (Figure 2C), but improved on Days 11 and
16, exhibiting overall improvements with time. Significant
differences were noted on Days 11 and 16 between the
Control and TJ-14 groups and the saline and TJ-14 groups
(Figure 2C). Intragroup comparisons revealed significant
differences between Days 9, 11 and 16 in the TJ-14 group.
Oral Bacterial Count Measurements
Oral bacterial counts slightly decreased over time in all
three groups (Figure 2D), with the largest decrease being
observed in the TJ-14 group, followed by the saline group.
The steepest reduction in bacterial counts occurred in the
TJ-14 group. Significant differences were observed
between all groups, except for the Control and saline
groups on Days 9 and 11 (Figure 2D). Significant differ-






























































































Figure 2 Evaluation of a rat chemotherapy-induced stomatitis model.
Notes: (A) Changes in body weights of rats in the three groups; (B) Changes in stomatitis grades among the three groups of rats; (C) Changes in stomatitis scores among
the three groups of rats; (D) Changes in oral bacterial counts among the three groups. Counts slightly decreased over time in all three groups. *p<0.05.
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Suppression of Experimental
Inflammation by TJ-14 in vivo
The Control group (cold water application) showed a 10%
suppression in swelling (Figure 3A and C), whereas a 30%
suppression was noted in the TJ-14 group (p < 0.01;
Figure 3B and C).
TJ-14 Promotes the Viability and Invasion
of Keratinocytes and Fibroblasts in vitro
As shown in Figure 4A, TJ-14 significantly increased the
viability of PSVK1 and KD cells after 48 h of exposure
(p < 0.05). Wound closure was observed within 48 h in
TJ-14-treated PSVK1 and KD cells; in contrast, the process
was significantly slower in Control cells (Figure 4B and C).
Discussion
Vasoconstriction, blood clot formation, fibrin formation,
inflammatory cell infiltration, cell proliferation, neovascu-
larization, and epithelial regeneration all contribute to
wound healing in the oral mucosa. Local factors that
influence wound healing include an insufficient oxygen
supply, local infection, and the presence of foreign bodies,
while systemic factors include age, sex, circulatory impair-
ments, an immunocompromised status, the nutritional sta-
tus, systemic disease, and the use of concomitant
Suppression rate of swelling (%)
= Left auricle thickness (mm) - Right auricle thickness (mm) 
X 100













Figure 3 Experimental inflammatory rat model. PMA solution was applied to both sides of the rat auricle to cause inflammation.
Notes: (A) Rat auricle 6 h after applying ice water once every hour; (B) Rat auricle 6 h after applying TJ-14 once every hour; (C) Stronger anti–inflammatory effects in the
TJ-14 group than in the Control group. *p<0.05.
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Figure 4 In vitro cell proliferation and wound healing assays.
Notes: (A) PSVK1 shows a significantly higher cell proliferation rate after 72 h in the TJ-14 (300 μg/mL) group than in the Control group. Significantly higher proliferation
rate of KD cells in the TJ-14 groups than in PSVK1 cells in a concentration-dependent manner; (B) PSVK1 increases cell proliferation in the TJ-14 groups in a concentration-
dependent manner. The time required to close the gap was slightly earlier in KD cells than in PSVK1 cells; (C) Representative photographs of PSVK1 and KD cells treated
with TJ-14. Cells at wounding (0 h) and after 24 and 48 h. *p<0.05.
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medications, such as steroids and anticancer agents.1,32
Chemotherapy-induced stomatitis is characterized by the
adhesion of large numbers of oral bacteria to the ulcerated
surface of the oral mucosa, which causes local infections.
Oral mucosal cells are damaged by the free radicals gen-
erated by anticancer drugs, which induces a strong inflam-
matory reaction and the formation of erosions and ulcers.
In addition, the oral mucosal epithelium is vulnerable to
mechanical stimulation, which easily erodes the surface.
Wound healing is delayed due to metabolic disorders
caused by anticancer drugs, and protection against infec-
tion is compromised by immunosuppression.10 Therefore,
local infections prolong healing in patients with stomatitis
and increase their susceptibility to further infection.
Local infection and delayed healing in chemotherapy-
induced stomatitis act synergistically to promote critical
colonization.33 Critical colonization may be prevented by
decreasing bacterial counts, which may be achieved via
chemical removal using pharmaceutical agents or physical
removal by rinsing or similar approaches. Critical coloni-
zation is attributed to large numbers of resident bacteria in
the mouth. Furthermore, ulcerated surfaces are covered by
necrotic material during stomatitis, which promotes the
proliferation of bacteria. Collectively, these factors reduce
the efficacy of pharmaceutical agents.29,34 In the present
study, bacterial counts were significantly lower in the
saline and TJ-14 groups than in the Control group, and
may be attributed to the physical removal of mucous and
necrotic substances by water flossing.
The antibacterial effects of TJ-14 have been categor-
ized into two types: those caused by the constituents of
TJ-14 itself and those by the antimicrobial peptides pro-
duced by the body. The former involves homogentisic
acid, baicalein, baicalin, berberine, coptisine, ginsenoside
Rb1, and 6-shogaol, which have been reported to exert
antibacterial effects against Gram-negative bacteria.
A previous study reported that TJ-14 was ineffective
against Gram-positive resident bacteria, and is less effec-
tive against the resident bacterial environment in the oral
cavity.23 On the other hand, antibacterial peptide produc-
tion involves 3,4-dihydroxybenzaldehyde, baicalin, and
ginsenoside Rb1, which act on oral mucosal epithelial
cells and are considered to protect them against bacterial
infection by enhancing the production of the antimicrobial
peptide calprotectin.35 The present results revealed mark-
edly lower numbers of bacteria in the TJ-14 group, sug-
gesting antibacterial activity in the mucosa of anticancer
drug-induced stomatitis.
No significant differences were observed in body
weight changes or food intake on Days 9 and 11 between
the three groups. A decreased food intake was noted after
the onset of stomatitis along with a corresponding reduc-
tion in body weight, and these changes were attributed to
the pain associated with stomatitis. On Day 16, body
weights were higher in the TJ-14 group than in the
Control and saline groups, and may have been due to an
increased food intake because pain during eating was
alleviated by the healing of stomatitis.
The growth of granulation tissues is an important step
in the oral mucosal repair throughout the healing process
of stomatitis. Fibroblasts play the most important role
also in the formation of granulation tissues. During the
repair process, fibroblasts migrate, proliferate and secrete
lots of collagen fibers and matrix components to form
granulation tissues along with new capillaries. They also
compensate for tissue defects and create the conditions
for epidermal keratinocytes to cover them.36 Significant
increases in the cell proliferation rate and cell migration
in a concentration-dependent manner were observed in
epidermal keratinocytes and fibroblasts in the TJ-14
group. Furthermore, macroscopic and histopathological
findings indicated more rapid healing in the TJ-14
group than in the Control and saline groups. The repair
of the oral mucosa was considered to be promoted by the
cell migration-promoting effects of TJ-14.
The present results did not support the analgesic and
free-radical-scavenging effects of TJ-14. However, the
anti–inflammatory, wound healing, and antibacterial prop-
erties of TJ-14 play important roles in stomatitis, suggest-
ing its potential to promote healing in stomatitis.
Among the seven components in TJ-14, those contri-
buting to its antibacterial, healing-promoting, and anti–
inflammatory effects have not yet been identified.
Furthermore, the synergistic effects of each herbal medi-
cine remain unclear. Therefore, future studies are needed
to investigate these properties in more detail. Additionally,
we think it necessary to compare the effectiveness of TJ-
14 for this disease with those of other currently available
treatment methods in the future.
The present results suggest that the local application of
TJ-14 is a higher-quality cancer treatment. The role of TJ-
14 is expected to increase in importance as newly devel-
oped cancer drugs exert their expected effects.
Nevertheless, the present results suggest that TJ-14 is
useful as an agent in cancer support therapy.
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